There is an open call in the FWF Science Communication Programme for science communication activities that aim to communicate scientific content from FWF-funded projects to relevant target groups. Application deadline: 9 September 2020. Open Science – Life Sciences in Dialogue with its expertise in science communication is available as partner for project proposals. The name says it all: Open Science is all about making life sciences available to everyone. The team of science communicators works in a wide variety of projects to stimulate discussion about life science topics and bring scientists together with school pupils, teachers and anyone else interested in learning more. If you are interested, please contact Brigitte Gschmeidler (This email address is being protected from spambots. You need JavaScript enabled to view it.) and/or Alexandra Schebesta (This email address is being protected from spambots. You need JavaScript enabled to view it.). More about Open Science – Life Sciences in Dialogue: www.openscience.or.at FWF Call: https://www.fwf.ac.at/en/research-funding/fwf-programmes/science-communication-programme-wisskomm/  

EURAXESS Career Orientation tool

Wednesday, 24 June 2020 10:57
No limits: explore your career as a researcher   The 'No limits' toolkit for researchers highlights resources to help you identify what's important for you in your career plan to build on your skills and knowledge consider a wide range of career options make a plan to reach your professional development goals The toolkit includes advice, quizzes to help you explore your own needs and links to resources, information and opportunities. To the toolkit Euraxess Austria | https://www.facebook.com/euraxessVIENNA
World-leading plasma companies collaborate to accelerate the development of a potential COVID-19 hyperimmune therapy. Takeda has been working intensively on the development of a potential plasma-derived therapy for the treatment of COVID-19 since the beginning of the corona crisis. At the beginning of April, Takeda Pharmaceutical Company Limited and CSL Behring announced the establishment of a global plasma alliance to accelerate the development of a potential therapy to treat people with serious complications from COVID-19. Four other plasma companies have already joined the alliance, such as Biotest, BPL, LFB, and Octapharma. “Unprecedented times call for bold moves,” said Julie Kim, President of Plasma-Derived Therapies Business Unit, Takeda. “We collectively agree that by collaborating and bringing industry resources together, we could accelerate bringing a potential therapy to market as well as increase the potential supply. We invite companies and institutions focusing on plasma to support or join our alliance.” Thomas R.…

Page 1 of 5